Production of live attenuated oral poliomyelitis vaccine (OPV) requires rigorous neurovirulence safety testing of each vaccine lot, currently carried out in monkeys. It has been reported that a change from 472-U to 472-C in the type 3 OPV RNA is associated with an increased histologic lesion score produced upon intraspinal inoculation of the mutant virus in monkeys. We have developed a method, based on polymerase chain reaction, for measuring the relative abundance of these mutant sequences directly in vaccine preparations and used this method to evaluate the proportion of 472-C in 40 different lots of type 3 OPV. Six vaccine lots that had failed the intraspinal monkey neurovirulence test contained a higher proportion of 472-C than all other lots that had passed this test. OPV type 3 virus containing 472-C was rapidly selected during serial passages in African green monkey kidney cells that are used for manufacturing of the vaccine. We have also found that the wild-type poliovirus type 3 strain Leon/37, from which the vaccine strain was originally derived, contained a mixture of 472-U and 472-C sequences. No other mutations in OPV type 3 RNA have been detected by similar assays at position 2034, also associated with attenuation, or at several other positions reported to be altered in some vaccine preparations. Our results suggest that molecular diagnostics may provide a supplement or a potential alternative to animal testing of live attenuated vaccines.
The production ofthe Sabin live attenuated oral poliomyelitis vaccine (OPV) (1) (2) (3) (4) during the past 30 years has been rigorously controlled by neurovirulence tests in large numbers of monkeys (5) . Over the last 7 years the complete nucleotide sequences of genomes of all three antigenically distinct strains used in the production of the vaccine have been determined (6, 7) , making it possible to investigate the basis of OPV attenuation at the molecular level. The RNA of the type 3 vaccine strain (Leon 12a1b) has been found to have 7434 nucleotides and only 10 of them were different from the wild-type progenitor strain Leon/37 (8) . It has been shown that, following multiplication in the intestinal tract of vaccinees, there can be a quantitative difference in some of the properties of the ingested virus-e.g., reproductive capacity at higher temperature (rct) with or without change in neurovirulence as measured by intraspinal and intrathalamic tests in monkeys but not in chimpanzees (9) . Studies on type 3 viruses excreted by healthy children after ingestion of the trivalent OPV regularly showed a change in the nucleotide at position 472 from uridine (U), found in the genome ofthe type 3 vaccine strain, to cytosine (C), found in wild-type strains (8, 10, 11) . This mutation was shown to result in a quantitative increase in histologic lesion scores produced in monkeys after intraspinal inoculation of the virus (10, 11) . We have therefore asked whether this virus containing C at position 472 (472-C) can be detected in the preparations of vaccine and whether its amount can be correlated with the results of a strict test for acceptability as measured by the World Health Organization (WHO) intraspinal monkey neurovirulence test (5) .
Sequence changes in poliovirus RNA have been previously analyzed by direct sequencing of viral RNA (10, 12) , a method that is not particularly sensitive for detection of sequence variants present at low abundance. The advent of the polymerase chain reaction (PCR) technology (13, 14) provided a tool with which we could readily test type 3 vaccine preparations for changes at position 472. To accomplish this, we have developed a highly sensitive molecular assay for these mutants and used it to test 40 lots of type 3 OPV, produced by different manufacturers. We have also tested these vaccine preparations for mutations at several other positions associated with attenuation (position 2034) (10) or reported to be altered in some lots that failed the monkey neurovirulence test (positions 445, 448, and 449) (12) . The results of our assays showed correlation between the nucleotide substitution at position 472, but not at any other tested position, and the results of the intraspinal monkey neurovirulence test. 472-C mutants were rapidly selected during serial passages in African green monkey kidney (AGMK) cells that are used for manufacturing the vaccine. Our results suggest a potential use for molecular diagnostics in the testing of live attenuated vaccines.
MATERIALS AND METHODS
Virus Growth, RNA Isolation, and cDNA Preparation. Viral RNA was isolated directly from 0.4 ml of vaccine stocks or cell culture fluid by phenol extraction with 1% SDS at room temperature. AGMK cells were obtained from Quality Biologics (Gaithersburg, MD) and infected either with 0.1 tissue culture dose (TCD50) per cell ("low multiplicity") or 10 TCD50 per cell ("high multiplicity") of the appropriate virus stock. cDNA was synthesized with Moloney murine leukemia virus reverse transcriptase (SuperScript; Bethesda Research Laboratories) and random hexadeoxynucleotide primers (15 confirms the significance of this position as an important marker ofthe original type 3 attenuated poliovirus strain. We were interested to determine whether the vaccine-specific 472-U sequence arose during the isolation of the vaccine strain or preexisted in the original wild-type poliovirus. We have therefore analyzed the RNA from the wild Leon/37 strain that served as the progenitor for the Sabin live vaccine strain Leon 12alb. We found that two batches of the Leon/37 virus obtained from the American Tissue Culture Collection (ATCC) contained a mixture of 472-U and 472-C (Fig. 3) , The proportions of472-C and 472-U were determined by digestion of the PCR product with Mbo I and ftinfl restriction enzymes, respectively (the latter enzyme recognizes the 472-U sequence). Leon/37 virus (ATCC VR-1004 lot V-003-001-019 showed 78.43% 472-U and 21.64% 472-C. In contrast, Leon/37 virus contained in the ATCC VR-62 culture (that was prepared at ATCC by passaging three times in AGMK and once in LLC-MK2 rhesus monkey kidney continuous cell line) showed 9.16% 472-U and 90.14% 472-C (Fig. 3, lanes  4-6) . After one additional passage of the above ATCC VR-62 Leon/37 culture in the HEp-2 human epithelial carcinoma cell line at low multiplicity of infection, this strain possessed almost 100% 472-C (Fig. 3, lanes 7-9) . The sum of 472-U and 472-C amounts is very close to 100%, suggesting that no 472-A or 472-G could be detected in these virus preparations. This result demonstrates that a wild poliovirus isolate comprises a mixed population of virus particles and that the viruses containing 472-C in their RNA are selectively enriched under certain conditions.
We were interested to determine whether mutations in other regions of the viral genome can also contribute to an increased lesion score in the WHO monkey test. In addition to position 472, another position, 2034, has been suggested to play a functional role in the attenuation of poliovirus type 3 (11) . To test for reversion to the wild-type sequence at this position, we have amplified a DNA fragment spanning the region 1970-2070 of the virus genome and digested it with Mse I restriction enzyme, which is expected to cut the 2034-T-containing vaccine sequence, and with Sfa NI, which should cut the 2034-C-containing wild-type sequence (Fig. 4) . We found that whereas the latter enzyme cleaves wild-type Leon/37 sequence completely, we were unable to find any detectable amount of 2034-C either in lots of type 3 OPV that failed or passed the monkey test or in the vaccine virus that was passaged in cell culture under the conditions that favored the selection of 472-C revertants.
Weeks-Levy et al. (12) reported that by using direct sequencing they were able to detect mutations at positions 445, 448, and 449 in several type 3 poliovirus vaccine lots that failed the monkey neurovirulence test. To test for the presence of such mutations, we have amplified the DNA fragment corresponding to the region 409-532 of the virus genome and digested it with restriction enzymes that should discriminate between the vaccine and the mutated sequences (see Materials and Methods). We have found no mutations at any of these positions in 18 tested individual lots of vaccine that included those that failed and those that passed the intraspinal monkey test (data not shown). Instead, the DNA fragments obtained for all vaccine lots were cleaved completely with restriction enzymes recognizing unaltered sequence. The presence of C at position 472 apparently increases the translation efficiency of viral RNA (16) ; this increased efficiency is likely to provide the basis for the selective advantage of 472-C mutants during growth in AGMK cells as well as in human gut (10) and in a neuroblastoma cell line (17) . In this respect it is interesting to find out if 472-U also provides some selective advantage to the virus under some conditions and to understand the mechanism of attenuation of poliovirus in the Sabin vaccine. Our finding that the extremely virulent wild-type Leon/37 strain contained 472-U and 472-C indicates that an equilibrium between these forms may exist in the native virus population. From these data it is evident that the presence of 472-U in the vaccine strain cannot be regarded as a mutation, but rather it was present in the wild-type parental strain. Similarly, change of 472-U for 472-C taking place in vaccinees (10) cannot be regarded as a true "reversion." Another question raised by these findings is whether some other mutation(s) in the wild-type strain may modify the effect of 472-U mutation.
Several specific mutations have also been implicated as the determinants of attenuation in type 1 and type 2 polioviruses (18) (19) (20) . The approach used in the present study can be applied to determine which mutations may be predictive for increased neurovirulence in vaccines of these two types. Our results suggest that molecular assay of the OPV may provide a supplement or an alternative to the current monkey test of the final product and may also be used for the in-process monitoring of poliovirus vaccine production. Furthermore, analysis of the mutant frequency at key positions associated with attenuation may also serve as a general principle for molecular evaluation of other attenuated viral or bacterial vaccines.
